 |
Rotavirus Safety and Efficacy Trial (REST)
RotaTeq was studied
in one of the largest vaccine trials in history, REST.3,4
- REST
was specifically designed to evaluate safety with respect
to IS—an uncommon but naturally occurring event—and
other adverse events, and the efficacy of RotaTeq in the
prevention of
RGE.4
- Double-blind, placebo-controlled trial.3
- Among
vaccine recipients in REST, there were no confirmed cases
of intussusception (IS) within the 42-day period of dose
1.
Significant US enrollment
Before administering RotaTeq, please
read the Prescribing
Information and Patient
Product Information.
RotaTeq is a registered trademark of Merck & Co., Inc.
|
